<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987996</url>
  </required_header>
  <id_info>
    <org_study_id>2020000655</org_study_id>
    <nct_id>NCT04987996</nct_id>
  </id_info>
  <brief_title>GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients</brief_title>
  <official_title>Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Providence Cancer Center, Earle A. Chiles Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Providence Health &amp; Services</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety &amp; efficacy of combination drugs versus&#xD;
      placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will be registered, stratified by diagnosis (melanoma versus OHN cancer),&#xD;
      and the number of prior systemic therapies, and randomized to receive either GR-MD-02 +&#xD;
      pembrolizumab or pembrolizumab + placebo.&#xD;
&#xD;
      In addition to monitoring for toxicity and clinical response, blood and tumor samples will be&#xD;
      obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell&#xD;
      checkpoint inhibition.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study delayed due to ongoing discussions with the owner of one of the investigational agents.&#xD;
  </why_stopped>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">August 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate based on disease imaging</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 63 weeks.</time_frame>
    <description>Determine the objective response of GR-MD-02 + pembrolizumab versus pembrolizumab monotherapy in patients with advanced MM or HNSCC</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of GAL-3 expression</measure>
    <time_frame>Screening and Day 68</time_frame>
    <description>Compare GAL-3 expression in paired biopsies after GR-MD-02 + pembrolizumab or pembrolizumab monotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of predictive biomarker</measure>
    <time_frame>Day 85</time_frame>
    <description>Characterize MDSC expression over time as a predictive biomarker of response after GRMD02 + pembrolizumab or pembrolizumab monotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Immune-mediated adverse events</measure>
    <time_frame>From time of informed consent to week 63</time_frame>
    <description>Compare the frequency of immune-mediated adverse events after GR-MD-02 + pembrolizumab versus pembrolizumab + placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of antiviral immunity</measure>
    <time_frame>Day 85</time_frame>
    <description>Assess the biological activity of GR-MD-02 + pembrolizumab and in comparison to pembrolizumab monotherapy by measuring CD4+T cells with a memory phenotype (CD3+CD4+Ki67+CD25+FoxP3-CCR7-CD45RA-CD27+CD28+/-).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of antiviral immunity</measure>
    <time_frame>Day 85</time_frame>
    <description>Assess the biological activity of GR-MD-02 + pembrolizumab and in comparison to pembrolizumab monotherapy by measuring CD8+ T cells with effector phenotype (CD3+CD8+CD28-CD95+).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of antiviral immunity</measure>
    <time_frame>Day 85</time_frame>
    <description>Assess the biological activity of GR-MD-02 + pembrolizumab and in comparison to pembrolizumab monotherapy by measuring tumor-specific T cells using autologous and/or HLA-matched tumor when available.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Metastatic Melanoma</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>GR-MD-02 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pembrolizumab Monotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 mg/kg placebo in combination with standard pembrolizumab treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GR-MD-02</intervention_name>
    <description>Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.</description>
    <arm_group_label>GR-MD-02 + pembrolizumab</arm_group_label>
    <other_name>Galactoarabino-rhamnogalactouronate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive up to seventeen doses of placebo intravenously over 85 Days.</description>
    <arm_group_label>Pembrolizumab Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Patients will receive 200mg doses of pembrolizumab intravenously over 85 Days.</description>
    <arm_group_label>GR-MD-02 + pembrolizumab</arm_group_label>
    <arm_group_label>Pembrolizumab Monotherapy</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with unresectable or metastatic melanoma including unknown primary, mucosal&#xD;
             or uveal melanomas. Histological confirmation of melanoma will be required by previous&#xD;
             biopsy or cytology. Patients with recurrent or metastatic head and neck squamous cell&#xD;
             carcinoma (HNSCC) with disease progression during or after platinum-containing&#xD;
             chemotherapy are eligible. PD-L1 testing is not needed for OHN cancers.&#xD;
&#xD;
          -  Patients who have received anti-PD1 or anti-PD-L1 in the past are eligible if it has&#xD;
             been at least 6 months since the last anti-PD-1 or PD-L1 dose, they meet all other&#xD;
             eligibility criteria and progression of malignancy has been documented on imaging.&#xD;
             Progression for this patient subset is defined as the appearance of one or more new&#xD;
             metastatic sites, or a 5% or greater increase in the sum of diameter of target lesions&#xD;
             or an unequivocal increase in non-target site. Treatment naïve melanoma patients are&#xD;
             eligible.&#xD;
&#xD;
          -  Patients must be ≥ 18 years of age.&#xD;
&#xD;
          -  ECOG performance status of 0-2.&#xD;
&#xD;
          -  Women of childbearing potential must have a serum or urine pregnancy test performed&#xD;
             within 72 hours prior to the start of protocol treatment. The results of this test&#xD;
             must be negative in order for the patient to be eligible. In addition, women of&#xD;
             childbearing potential as well as male patients must agree to take appropriate&#xD;
             precautions to avoid pregnancy.&#xD;
&#xD;
          -  No active bleeding.&#xD;
&#xD;
          -  Anticipated lifespan greater than 12 weeks.&#xD;
&#xD;
          -  Patients must sign a study-specific consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have previously received a galectin antagonist.&#xD;
&#xD;
          -  Patients with active autoimmune disease except for autoimmune thyroiditis or vitiligo&#xD;
             (see Appendix C).&#xD;
&#xD;
          -  Patients with history of autoimmune colitis.&#xD;
&#xD;
          -  Patients with untreated brain metastases. Patients with treated brain metastases who&#xD;
             demonstrate control of brain metastases with follow-up imaging 4 or more weeks after&#xD;
             initial therapy are eligible.&#xD;
&#xD;
          -  Patients requiring other systemic oncologic therapy, including experimental therapies.&#xD;
&#xD;
          -  Patients with active infection requiring antibiotics.&#xD;
&#xD;
          -  Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo&#xD;
             or fetus.&#xD;
&#xD;
          -  Need for steroids at greater than physiologic replacement doses. Inhaled&#xD;
             corticosteroids are acceptable.&#xD;
&#xD;
          -  Laboratory exclusions (to be performed within 28 days of enrollment):&#xD;
&#xD;
               -  WBC &lt; 3.0 x 109/L&#xD;
&#xD;
               -  Hgb &lt; 9.0 g/dL&#xD;
&#xD;
               -  AST or ALT &gt; 1.5 times ULN&#xD;
&#xD;
               -  Total bilirubin &gt; 1.9 g/dL, unless due to Gilbert's Syndrome. If Gilbert's&#xD;
                  Syndrome is present by clinical history, then direct bilirubin must by &lt; 3.0&#xD;
                  g/dl.&#xD;
&#xD;
               -  Known history of HIV&#xD;
&#xD;
               -  Known history of Hepatitis B&#xD;
&#xD;
               -  Known history of Hepatitis C&#xD;
&#xD;
               -  INR &gt; 1.5x ULN&#xD;
&#xD;
          -  Inability to give informed consent and comply with the protocol. Patients must be&#xD;
             judged able to understand fully the investigational nature of the study and the risks&#xD;
             associated with the therapy.&#xD;
&#xD;
          -  Any medical condition that in the opinion of the Principal Investigator would&#xD;
             compromise the safety or conduct of the study procedures.&#xD;
&#xD;
          -  Unresolved immune-mediated pneumonitis, diarrhea, elevation of hepatocellular enzymes&#xD;
             or other toxicities requiring greater than physiological replacement doses of&#xD;
             steroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan D. Curti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Portland Providence Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HNSCC</keyword>
  <keyword>MM</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>GR-MD-02</keyword>
  <keyword>Galectin Inhibitor</keyword>
  <keyword>GRMD-02</keyword>
  <keyword>GRMD002</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

